TGF-β-regulated different iron metabolism processes in the development and cisplatin resistance of ovarian cancer

Jianfa Wu1,2, Qianyi Liao3, L I Zhang1,2

  • 1Department of Gynecology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.

Oncology Research
|January 8, 2024
PubMed

Insights

Altered iron metabolism processes (DIMP) impact ovarian cancer initiation, chemo-resistance, and prognosis. Targeting DIMP offers potential for personalized ovarian cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The role of distinct iron metabolism processes (DIMP) in ovarian cancer is not fully understood.
  • Investigating DIMP is crucial for understanding ovarian cancer development and progression.

Purpose of the Study:

  • To investigate the impact of different iron metabolism processes (DIMP) on ovarian cancer initiation, development, and prognosis.
  • To identify specific iron metabolism genes and their alterations in ovarian cancer.

Main Methods:

  • Utilized gene chips and databases (e.g., cBioPortal, Kaplan-Meier plotter) to analyze DIMP in 1669 serous ovarian cancer cases.
  • Examined gene mutations, expression levels in cancer vs. normal tissues, and chemo-resistance.
  • Assessed the correlation between DIMP gene expression and patient survival.

Main Results:

  • Identified mutations in key iron import (transferrin receptor, melanotransferrin) and regulation genes (glucose-6-phosphate isomerase, hepcidin antimicrobial peptide).
  • Observed altered expression of iron utilization, export, and storage genes in ovarian cancer, with distinct patterns in cisplatin-resistant cells.
  • Found that altered expression of iron import and export genes correlates with poor progression-free survival.

Conclusions:

  • DIMP play multifaceted roles in ovarian cancer initiation, chemo-resistance, and prognosis.
  • TGF-β signaling influences iron metabolism gene expression, particularly in iron storage.
  • Targeting DIMP presents a promising strategy for developing tailored ovarian cancer therapies.